SecBot SecBot
Institutional Cluster

ACRS

Aclaris Therapeutics, Inc.
BULLISH
Impact 5/10
Horizonweeks Processed2mo ago
Institutional cluster: 10 buyers, 2 sellers (bullish)
Actionable Insight ▲ Bullish

The Q2 2026 13F cluster shows broad institutional accumulation, but the 45-day reporting lag means these positions were established by June 30 — the stock has already rallied ~12% since the Q2 earnings beat on Aug 6. The cluster is dominated by passive index funds (BlackRock, State Street) which may reflect ACRS's inclusion in broader small-cap indices rather than active conviction. Watch for the H2 2026 pipeline catalysts (ATI-052, bosakitug) as the real catalysts; the 13F data alone does not justify chasing the move at current levels.

DirectionBullish
Confidencemedium
Horizonweeks
Latest settled — T+20d
ACRS ▼ -5.74% at T+20d
LONG call ✗ call lost -5.74% · α vs SPY -3.84% · entry $5.84 → $5.51
Next anchor: T+60d in 8d
Latest observation: T+51 -30.17% FF3 residual α
Entry = T+0 close
Aug 11, 2026
via day close
T+1d
+0.34%
call +0.34% · α -0.36%
$5.86
settled 3mo ago
T+5d
+10.27%
call +10.27% · α +10.72%
$6.44
settled 2mo ago
T+20d
-5.74%
call -5.74% · α -3.84%
$5.51
settled 7w ago
T+60d
Pending
in 8d

Executive Summary

A strong institutional accumulation cluster in Aclaris Therapeutics during Q2 2026, with 10 buyers adding $43.5M in net new positions vs only 2 trivial sellers. The buying is dominated by mega-passive index funds (BlackRock +$25.3M, State Street +$9.7M) and active managers (Panagora +$5.3M, BNY Mellon +$0.7M), suggesting broad-based conviction ahead of upcoming pipeline catalysts (ATI-052 Phase 1b POC, bosakitug Phase 2 results in H2 2026). The cluster aligns with the company's Q2 earnings beat and extended cash runway, but the lack of insider buying (institutions-only signal) tempers conviction — this is a passive-driven rebalancing cluster rather than an activist or informed-trading signal.

Key Financial Metrics

Direction
accumulating
Buy Value
$43.5M
Sell Value
$5.0K
Net Flow
$43.5M

Institutional Positions

Net institutional flow: $43.5M

▲ Buyers (10)

InstitutionActionChangePosition ValueValue Δ
BlackRockADD+35.5%$53.1M$25.3M
State StreetADD+62.1%$17.2M$9.7M
Panagora Asset ManagementDOUBLED+170%$7.2M$5.3M
Bank Of New York MellonADD+36.5%$1.5M$719.0K
NuveenDOUBLED+135.9%$1.5M$1.0M

▼ Sellers (2)

InstitutionActionChangePrev ValueValue Δ
Vontobel HoldingTRIM-28%$94.0K$1.0K
Hightower AdvisorsTRIM-28.9%$1.1M$4.0K

Key Facts

  • 10 institutional buyers added $43.5M in net new ACRS positions during Q2 2026
  • BlackRock increased holdings by $25.3M (+35.5%) to $53.1M, now the largest holder
  • State Street added $9.7M (+62.1%) to $17.2M
  • Panagora Asset Management doubled its position by $5.3M (+170%) to $7.2M
  • Only 2 sellers (Vontobel, Hightower) with trivial net changes totaling $5K
  • No open-market insider buying detected in the window — institutions-only signal
  • Q2 2026 earnings showed net loss of $21.5M ($-0.15/share) on $1.6M revenue, slightly beating consensus EPS of $-0.16
  • Company raised $40.2M in ATM post-quarter, extending cash runway through 2028
  • Upcoming catalysts: ATI-052 Phase 1b POC data and bosakitug Phase 2 results in H2 2026

Financial Impact

10 institutional buyers accumulated $43.5M in net new positions (total buying value $43.5M) while 2 sellers reduced holdings by only $5K — a 99.99% net-buying cluster by dollar value

institutional ownershipfloat concentration

Risk Factors

  • 45-day 13F reporting lag — positions may have been unwound since quarter-end
  • Cluster dominated by mega-passive index funds (BlackRock, State Street) which may reflect index rebalancing, not active conviction
  • No insider buying to corroborate the institutional signal
  • Pre-revenue biotech with no approved products — binary pipeline risk
  • Q2 revenue declined 8.3% YoY to $1.6M, widening net loss

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 institutional 13F filing from SEC EDGAR.

DocumentAccession Number
INST-CLUSTER Data (Synthetic)inst-cluster-ACRS-2026-Q2
11 reports for ACRS
Performance horizon
100% Hit rate @ T+5 4 of 4 directional calls Went positive at some point 4 of 4 best @ T+60▲ +47.87%Feb 28, 2026
Filters
Rows
Reports for ACRS — sortable, filterable
TypeNow
Aug 11, 2026
10w ago
Institutional Cluster
BULLISH ★ 5/10
$5.84 $6.44▲ +10.27%▲ +10.72%—
Aug 6, 2026
11w ago
8-K
NEUTRAL ★ 4/10
$6.09 $5.86▼ −3.78%▼ −4.99%—
Apr 28, 2026
25w ago
8-K
BULLISH ★ 8/10
$4.22 $4.75▲ +12.56%▲ +10.87%—
Apr 28, 2026
25w ago
Press Release
BULLISH ★ 7/10
$4.22 $4.75▲ +12.56%▲ +10.87%—
Apr 23, 2026
26w ago
DEFA14A
NEUTRAL ★ 2/10
$4.55 $4.47▼ −1.76%▼ −3.24%—
Mar 27, 2026
30w ago
Press Release
BULLISH ★ 8/10
$3.52 $3.80▲ +7.95%▲ +4.09%—
Mar 20, 2026
31w ago
Press Release
NEUTRAL ★ 3/10
$3.69 $3.52▼ −4.61%▼ −2.46%—
Mar 18, 2026
31w ago
Press Release
NEUTRAL ★ 5/10
$3.66 $3.59▼ −1.91%▼ −1.20%—
Mar 11, 2026
32w ago
8-K
NEUTRAL ★ 3/10
$3.51 $3.74▲ +6.55%▲ +7.53%—
Feb 28, 2026
34w ago
Institutional Cluster
BULLISH ★ 6/10
$3.05 $3.39▲ +11.15%▲ +12.36%—
Showing 10 of 11

US Market Status

Market Closed — Opens Wed (13h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026